Lack of acquired resistance in HER2-positive breast cancer cells after long-term HER2 siRNA nanoparticle treatment.

about

Lack of acquired resistance in HER2-positive breast cancer cells after long-term HER2 siRNA nanoparticle treatment.

Item

http://www.wikidata.org/entity/Q55091931

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh

2018年學術文章

@zh-hant

name

Lack of acquired resistance in ...... siRNA nanoparticle treatment.

@en

Lack of acquired resistance in ...... siRNA nanoparticle treatment.

@nl

type

Item

label

Lack of acquired resistance in ...... siRNA nanoparticle treatment.

@en

Lack of acquired resistance in ...... siRNA nanoparticle treatment.

@nl

prefLabel

Lack of acquired resistance in ...... siRNA nanoparticle treatment.

@en

Lack of acquired resistance in ...... siRNA nanoparticle treatment.

@nl

P1476

Lack of acquired resistance in ...... siRNA nanoparticle treatment.

@en

P2093

Joe W Gray

http://www.w3.org/2001/XMLSchema#string

Moataz Reda

http://www.w3.org/2001/XMLSchema#string

Wassana Yantasee

http://www.w3.org/2001/XMLSchema#string

Worapol Ngamcherdtrakul

http://www.w3.org/2001/XMLSchema#string

Zhi Hu

http://www.w3.org/2001/XMLSchema#string

P2860

HER2 kinase domain mutation results in constitutive phosphorylation and activation of HER2 and EGFR and resistance to EGFR tyrosine kinase inhibitors

Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer.

Activating HER2 mutations in HER2 gene amplification negative breast cancer

Receptor tyrosine kinase ERBB4 mediates acquired resistance to ERBB2 inhibitors in breast cancer cells.

Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer

HER2 activating mutations are targets for colorectal cancer treatment

Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer

The HER-2/neu Oncogene in Breast Cancer: Prognostic Factor, Predictive Factor, and Target for Therapy.

Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study.

Differential sensitivity of ERBB2 kinase domain mutations towards lapatinib

P304

e0198141

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1371/JOURNAL.PONE.0198141

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Shenda Gu

P577

2018-06-07T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29879129

http://www.w3.org/2001/XMLSchema#string

P921

nanoparticle

P932

5991725

http://www.w3.org/2001/XMLSchema#string